Tags

Type your tag names separated by a space and hit enter

Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
J Gastroenterol Hepatol. 2013 Mar; 28(3):450-5.JG

Abstract

BACKGROUND AND AIM

Cirrhotic patients are predisposed to intestinal bacterial overgrowth with translocation of bacterial products which may deteriorate liver hemodynamics. Having shown that short-term administration of rifaximin improves liver hemodynamics in decompensated cirrhosis, we conducted this study to investigate the effect of intestinal decontamination with rifaximin on the long-term prognosis of patients with alcohol-related decompensated cirrhosis (Child-Pugh > 7) and ascites.

METHODS

Patients who had received rifaximin and showed improved liver hemodynamics were enrolled in the current study and continued to receive rifaximin (1200 mg/day). Each patient was matched by age, sex, and Child-Pugh grade to two controls and followed up for up to 5 years, death or liver transplantation. Survival and risk of developing portal hypertension-related complications were compared between rifaximin group and controls.

RESULTS

Twenty three patients fulfilled the inclusion criteria and matched with 46 controls. Patients who received rifaximin had a significant lower risk of developing variceal bleeding (35% vs. 59.5%, P = 0.011), hepatic encephalopathy (31.5% vs. 47%, P = 0.034), spontaneous bacterial peritonitis (4.5% vs. 46%, P = 0.027), and hepatorenal syndrome (4.5% vs. 51%, P = 0.037) than controls. Five-year cumulative probability of survival was significantly higher in patients receiving rifaximin than in controls (61% vs. 13.5%, P = 0.012). In the multivariate analysis, rifaximin administration was independently associated with lower risk of developing variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome, and higher survival.

CONCLUSIONS

In patients with alcohol-related decompensated cirrhosis, long-term rifaximin administration is associated with reduced risk of developing complications of portal hypertension and improved survival.

Authors+Show Affiliations

Hepatogastroenterology Unit, 1st Department of Medicine-Propaedeutic, Medical School, Athens University, Laiko General Hospital, Athens, Greece. jvlachog@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

23216382

Citation

Vlachogiannakos, Jiannis, et al. "Long-term Administration of Rifaximin Improves the Prognosis of Patients With Decompensated Alcoholic Cirrhosis." Journal of Gastroenterology and Hepatology, vol. 28, no. 3, 2013, pp. 450-5.
Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28(3):450-5.
Vlachogiannakos, J., Viazis, N., Vasianopoulou, P., Vafiadis, I., Karamanolis, D. G., & Ladas, S. D. (2013). Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. Journal of Gastroenterology and Hepatology, 28(3), 450-5. https://doi.org/10.1111/jgh.12070
Vlachogiannakos J, et al. Long-term Administration of Rifaximin Improves the Prognosis of Patients With Decompensated Alcoholic Cirrhosis. J Gastroenterol Hepatol. 2013;28(3):450-5. PubMed PMID: 23216382.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. AU - Vlachogiannakos,Jiannis, AU - Viazis,Nikos, AU - Vasianopoulou,Panagiota, AU - Vafiadis,Irene, AU - Karamanolis,Dimitrios G, AU - Ladas,Spiros D, PY - 2012/10/12/accepted PY - 2012/12/11/entrez PY - 2012/12/12/pubmed PY - 2013/8/27/medline SP - 450 EP - 5 JF - Journal of gastroenterology and hepatology JO - J Gastroenterol Hepatol VL - 28 IS - 3 N2 - BACKGROUND AND AIM: Cirrhotic patients are predisposed to intestinal bacterial overgrowth with translocation of bacterial products which may deteriorate liver hemodynamics. Having shown that short-term administration of rifaximin improves liver hemodynamics in decompensated cirrhosis, we conducted this study to investigate the effect of intestinal decontamination with rifaximin on the long-term prognosis of patients with alcohol-related decompensated cirrhosis (Child-Pugh > 7) and ascites. METHODS: Patients who had received rifaximin and showed improved liver hemodynamics were enrolled in the current study and continued to receive rifaximin (1200 mg/day). Each patient was matched by age, sex, and Child-Pugh grade to two controls and followed up for up to 5 years, death or liver transplantation. Survival and risk of developing portal hypertension-related complications were compared between rifaximin group and controls. RESULTS: Twenty three patients fulfilled the inclusion criteria and matched with 46 controls. Patients who received rifaximin had a significant lower risk of developing variceal bleeding (35% vs. 59.5%, P = 0.011), hepatic encephalopathy (31.5% vs. 47%, P = 0.034), spontaneous bacterial peritonitis (4.5% vs. 46%, P = 0.027), and hepatorenal syndrome (4.5% vs. 51%, P = 0.037) than controls. Five-year cumulative probability of survival was significantly higher in patients receiving rifaximin than in controls (61% vs. 13.5%, P = 0.012). In the multivariate analysis, rifaximin administration was independently associated with lower risk of developing variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome, and higher survival. CONCLUSIONS: In patients with alcohol-related decompensated cirrhosis, long-term rifaximin administration is associated with reduced risk of developing complications of portal hypertension and improved survival. SN - 1440-1746 UR - https://www.unboundmedicine.com/medline/citation/23216382/Long_term_administration_of_rifaximin_improves_the_prognosis_of_patients_with_decompensated_alcoholic_cirrhosis_ L2 - https://doi.org/10.1111/jgh.12070 DB - PRIME DP - Unbound Medicine ER -